{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 3,
    "total_evidence": 6
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains: A/West Virginia 30 2022 (A/Wisconsin/67/2022 pdm 09 like virus) (H1 N1), A/Massachusetts/18/ 2022 (H3 N2) and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote explicitly states the total and per-strain hemagglutinin (HA) content in Flublok, which is 135 mcg per dose (45 mcg per strain), supporting the claim that Flublok contains 3x the HA antigen content of standard-dose flu vaccines (which typically contain 15 mcg per strain)."
    },
    {
      "id": 2,
      "quote": "5. Treanor JJ, Schiff GM, Hayden FG, et.al. Safety and immunogenicity of a baculovirus expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "relevance_explanation": "This reference is cited in the context of clinical studies and directly links Flublok (a baculovirus-expressed hemagglutinin vaccine) to immunogenicity outcomes, supporting the claim that higher HA content is associated with greater immunogenicity compared to standard-dose vaccines."
    },
    {
      "id": 3,
      "quote": "3. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine 2009 Vol 28 pp 379 385",
      "relevance_explanation": "This reference is cited as a comparative immunogenicity study between Flublok (rHA) and standard trivalent inactivated vaccines (TIVs), supporting the claim that Flublok's higher HA content is linked to greater immunogenicity."
    },
    {
      "id": "comp_1",
      "quote": "Flublok contains recombinant HA proteins of the three strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination inhibition (HI) antibodies to each virus strain represented.",
      "relevance_explanation": "This quote explicitly states that Flublok contains recombinant hemagglutinin (HA) proteins as antigens, which are responsible for inducing an immune response. This supports the claim that the HA content is directly linked to immunogenicity.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Flublok is standardized according to United States Public Health Service (USPHS) requirements. For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains: A/West Virginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/2022 (H3N2), and B/Austria/1359417/2021.",
      "relevance_explanation": "This quote provides the exact HA content per dose in Flublok, which is three times the standard 15 mcg per strain found in standard-dose flu vaccines, directly supporting the claim about antigen content.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of Flublok trivalent recombinant baculovirus expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "relevance_explanation": "This reference is cited in the context of clinical studies evaluating the immunogenicity of Flublok, supporting the claim that its higher HA content is linked to greater immunogenicity compared to standard-dose vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}